Cipla Launches Generic Weight-Loss Drug

The active ingredient in Saxenda®, liraglutide, was first developed by Novo Nordisk and approved in 2010 as Victoza®, a treatment for type 2 diabetes. It was later approved specifically for weight management in 2014 under the brand name Saxenda. Liraglutide is a GLP-1 receptor agonist that mimics a naturally occurring hormone to help regulate appetite and food intake. The introduction of a generic version of a drug typically leads to a significant decrease in cost for consumers. The list price for a 30-day supply of Saxenda® can be over $1,300 without insurance. The entry of a generic alternative is a key factor in making medications more affordable. Novo Nordisk's obesity care segment, which includes Saxenda® and Wegovy®, saw sales increase by 57% in 2024, reaching over DKK 65 billion. The company holds a dominant position in the global branded obesity market. The high demand for these medications underscores the significant market Cipla's generic is entering. This launch continues Cipla's strategy of expanding its footprint in the U.S. market through a combination of in-house development, acquisitions, and strategic partnerships. The company has previously partnered with Orbicular Pharma on other generic medications, indicating an established working relationship. The market for weight-management drugs in the United States is substantial, with recent data showing that over 40% of U.S. adults have obesity. The high prevalence of obesity contributes to a significant demand for effective and accessible treatment options.